GSK India Managing Director Hasit Joshipura: An Interview With PharmAsia News (Part 2 of 2)
This article was originally published in The Pink Sheet Daily
Joshipura discusses what lies ahead for India’s largest multinational drug company.
You may also be interested in...
GSK India Managing Director Hasit Joshipura On What Lies Ahead For India’s Largest Multinational Drug Company: An Interview With PharmAsia News (Part 1 of 2)
GlaxoSmithKline India Managing Director Hasit Joshipura is known as one of the most aggressive multinational pharma directors in India in terms of expansion strategy. Some top GSK officials say he was brought in at the helm with the task of making GSK sharper in its marketing approach. Joshipura presented those capabilities in his earlier stint as the managing director at Johnson & Johnson India. Joshipura sat down with PharmAsia News' India bureau to discuss what lies ahead for India's largest multinational drug company.
GSK “Delighted” By India’s Supreme Court Ruling In 10-Year Exclusive Marketing Rights Battle Over Avandia
MUMBAI - The Supreme Court of India has upheld a Calcutta High Court decision to grant exclusive marketing rights to GlaxoSmithKline's anti-diabetes drug Avandia in a landmark judgment that will have wide repercussions on product patent applications by multinational companies in India
MUMBAI - India's largest multinational drug maker GlaxoSmithKline is planning a big entry into the country's rural pharmaceutical market. An exhaustive plan is being hammered out to understand the dynamics of the rural medicine market so that GSK can position itself correctly in the intensely price-sensitive market segment